AJMC January 13, 2026
Key Takeaways
- AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade.
- The TrumpRx program will expand direct-to-patient offerings, improving access to medications like Humira, Alphagan, Combigan, and Synthroid.
- In exchange for pricing concessions, AbbVie receives exemptions from tariffs and future price mandates, aligning with Trump’s drug pricing priorities.
- The Trump administration’s initiative seeks voluntary drug pricing concessions from pharmaceutical companies, aiming to align US prices with international levels.
As part of the deal, AbbVie is expanding its direct-to-patient offerings through the TrumpRx program.
AbbVie on Tuesday announced a voluntary agreement with the Trump administration aimed at expanding access to medicines and lowering costs for US patients...
Today's Sponsors
Today's Sponsor